Xilio Therapeutics Inc (NAS:XLO)
$ 1.31 -0.13 (-9.03%) Market Cap: 57.58 Mil Enterprise Value: -3.85 Mil PE Ratio: 0 PB Ratio: 1.72 GF Score: 34/100

Xilio Therapeutics Inc at Cowen IO Next Summit (Virtual) Transcript

Nov 11, 2022 / 06:40PM GMT
Release Date Price: $2.5 (+2.29%)
Marc Frahm
Cowen - MD, Healthcare

Hi, welcome to the next session of the sixth annual Cowen IO Next Summit. We are really pleased to have with us today for the next session, Marty Huber, President and Head of R&D from Xilio Therapeutics. And I would remind all the investors on the line that while I do have a question list that I can run through with Marty, we'd love to have this be as interactive as possible. So you can submit questions either through the chat function of the webcast or you can email me directly at [email protected].

Questions & Answers

Marc Frahm
Cowen - MD, Healthcare

So maybe just to start off, Marty, just to level set people who may not be in depth truly familiar with Xilio, just can you give a brief overview of the GPS platform, NK, how it works, and why it's ideally suited for delivering cytokines or other biologics?

Marty Huber
Xilio Therapeutics, Inc. - President & Head of R&D

Thank you. And first of all, I'll say hello from Boston at [Fitzy]. We're actually at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot